March 8, 2017
Professor Nancy Rigotti, MD, will chair a symposium entitled “Cytisine Update: Moving Research Forward Toward a Globally Affordable Tobacco Cessation Medication”
Other presenters include Natalie Walker, PhD; David Shurtleff, PhD; SooHee Jeong, PhD; and Kamran Siddiqi, PhD.
MILL VALLEY, Calif., BOTHELL, Wash. and VANCOUVER, British Columbia, March. 8, 2017 /PRNewswire/ — Achieve Life Sciences, Inc. (“Achieve”), and OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) (“OncoGenex”) today announced that the Society for Research in Nicotine and Tobacco (SRNT) will be holding a symposium on cytisine research at this year’s annual conference, to be held at the Firenze Fiera Congress and Exhibition Center in Florence, Italy from March 7th – 11th. The cytisine symposium will be on Friday 10th March at 10:30 a.m.
Professor Nancy Rigotti, MD, Massachusetts General Hospital/Harvard Medical School is chairing the symposium, with presentations from Associate Professor Natalie Walker, PhD, National Institute for Health Innovation, University of Auckland, on “Cytisine versus Varenicline for Smoking Cessation: Two Clinical Trials from the Australasian Cytisine Trialist Group” and “The Challenge to Getting Cytisine Licensed For Use Worldwide: Policy Considerations”. Dr. Walker conducted the 2014 CASCAID Phase 3 clinical trial – a 1,310 patient trial comparing cytisine to nicotine replacement therapy.
Further to Achieve’s collaborat